increased. Furthermore, if the addition of a LABA has had no added benefit this may be stopped, with the patient continuing solely with the higher dose of corticosteroid. If the disease remains poorly controlled after addition of a LABA therapy, it is recommended that a leukotriene receptor antagonist, a theophylline or slow-release b-agonist tablets be considered.

The guidelines state that for regular preventer therapy, the use of a short-acting anticholinergic is generally of no value. Furthermore, treatment plans do not mention the use of long-acting anticholinergic agents, such as antimuscarinic agents, and no long-acting antimuscarinics have been approved for the treatment of asthma.


Corticosteroid monotherapy and combination therapy with a LABA have become established methods for the maintenance treatment of asthma. However, there exists a need for alternative therapies for the effective pharmacological management of asthma, for example, for those patients that are currently poorly controlled on any approved and recommended treatment plan.

Furthermore, there exists a need for alternative therapies that are able to improve patient compliance and hence efficacy over current treatment options.

SUMMARY ~~OF THE INVENTION~~

~~The present invention provides~~ In one embodiment, there is provided a novel pharmaceutical combination product comprising:

a) the compound of formula (I):



(I)

wherein X^- is a pharmaceutically acceptable anion;

and

b) a corticosteroid.

In one embodiment, the pharmaceutical combination product does not comprise any further therapeutically active agents.

In a further embodiment, the compound of formula (I) is umeclidinium bromide.

In a further embodiment, the corticosteroid is fluticasone furoate.

In a further embodiment, the pharmaceutical combination product comprises umeclidinium bromide and fluticasone furoate.


In a further embodiment, ~~the present invention provides~~ there is provided pharmaceutical combination products as herein disclosed for use in therapy, particularly in the treatment of inflammatory and respiratory tract diseases, such as asthma.

In a further embodiment, ~~the present invention provides~~ there is provided a method for the treatment of an inflammatory or respiratory disease, such as asthma, comprising administering to a patient in need thereof, a pharmaceutical combination product comprising the compound of formula (I) and a corticosteroid.

According to a first aspect, there is provided

a pharmaceutical combination product comprising

a) a compound of formula (I):



(I)

wherein X^- is a pharmaceutically acceptable anion selected from the group consisting of chloride, bromide, iodide, hydroxide, sulfate, nitrate, phosphate, acetate, trifluoroacetate, fumarate, citrate, tartrate, oxalate, succinate, mandelate, methanesulfonate and p-toluenesulfonate; and

b) fluticasone furoate present in an amount of 100mcg/dose;

and further wherein the product does not comprise any further therapeutically active agents.

According to a second aspect, there is provided a dry powder inhaler containing a product as disclosed herein which comprises two compositions presented separately in unit dose form, wherein the first composition comprises

i. umeclidinium bromide, and
ii. lactose, and
iii. magnesium stearate at an amount of about 0.6%w/w based on the total weight of the first composition;

and the second composition comprises

i. fluticasone furoate present in an amount of 100mcg/dose, and
ii. lactose.

According to a third aspect, there is provided a product as disclosed herein for use in therapy.

According to a fourth aspect, there is provided a product as disclosed herein for use in the treatment of inflammatory or respiratory tract diseases.

According to a fifth aspect, there is provided use of a product as disclosed herein, in the manufacture of a medicament for the treatment of inflammatory or respiratory tract diseases.